Apoptotic Effect of Co-Treatment with Valproic Acid and HS-1200 on Human Osteosarcoma Cells


Department of Oral Medicine, School of Dentistry, Pusan National University

INTRODUCTION

Valproic acid (VPA) is a well-known anticonvulsive agent and has been used in the treatment of epilepsy for almost 30 years. VPA emerged in 1997 as an antineoplastic agent as well, when findings indicated the substance inhibited proliferation and induced differentiation of primitive neuroectodermal tumor cells in vivo (Cinalli et al., 1997). Antitumor activity of VPA is associated with its targeting histone deacetylases. Bile acids and their synthetic derivatives induced apoptosis in various kinds of cancer cells and anticancer effects. It has been reported that the synthetic chenodeoxycholic acid (CDCA) derivatives showed apoptosis-inducing activity on various cancer cells in vitro. This study was undertaken to investigate the synergistic apoptotic effect of co-treatment with the histone deacetylases inhibitor, VPA and a CDCA derivative, HS-1200 on human osteosarcoma (HOS) cells.

Cell viability was evaluated by trypan-blue exclusion. Induction and augmentation of apoptosis were confirmed by Hoechst staining, flow cytometry (DNA hypoploidy and MMP change), Western blot analysis and immunofluorescent staining.

In this study, HOS cells co-treated with VPA and HS-1200 showed several lines of apoptotic manifestation such as nuclear condensations, the reduction of MMP, the decrease of DNA content, the release of cytochrome c into cytosol, the translocation of AIF onto nuclei, and activation of caspase-7, caspase-3 and PARP whereas each single treated HOS cells did not. Although the single treatment of 1 mM VPA or 25 μM HS-1200 for 48 h did not induce apoptosis, the co-treatment of them induced prominently apoptosis. Therefore our data provide the possibility that combination therapy of VPA and HS-1200 could be considered as a novel therapeutic strategy for human osteosarcoma.

Key words: Apoptosis, Valproic acid, HS-1200, Human osteosarcoma
conditions, such as hypoxia, hypoglycemia, and serum deprivation. Among these conditions, hypoxia is one of the key factors to trigger angiogenesis via the induction of angiogenic factors. Regulation of such gene expression through the acetylation of histone is highly involved in the control of angiogenesis. HDAC inhibitors were known to cause growth arrest, differentiation, or apoptosis of a variety of transformed cells in culture, including human bladder, breast, prostate, lung, ovary, colon cancer cells. Several classes of HDACs have been identified, which include organic hydroxamic acids (e.g., TSA and suberoyl anilide bishydroxamate [SAHA]), short-chain fatty acids (e.g., butyrate and valproic acid [VPA]), cyclic tetrapeptides (e.g., MS-275).

Valproic acid (VPA) is a well-known anticonvulsive agent and has been used in the treatment of epilepsy for almost 30 years. VPA emerged in 1997 as an antineoplastic agent as well, when findings indicated the substance inhibited proliferation and induced differentiation of primitive neuroectodermal tumor cells in vivo. Antitumor activity of VPA is associated with its targeting histone deacetylases. VPA in particular, was able to down-regulate class II HDAC protein levels significantly in several cells in contrast to TSA, which implies that VPA might be a more selective HDAC inhibitor than TSA.

Bile acids are polar derivatives of cholesterol essential for the absorption of dietary lipids and regulate the transcription of genes that control cholesterol homeostasis. Different bile acids exhibit distinct biological effects. Importantly, natural bile salts were reported to inhibit cell proliferation and induce apoptosis in various cells. Im et al. developed several ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) derivatives, and it has been reported that they had apoptosis-inducing effect in various cancer cells.

Cells undergoing apoptosis usually develop characteristic changes, including nuclear condensation and degradation of DNA into digonucleosomal fragments. Apoptotic cell death is thought to result ultimately from the proteolytic actions of caspase and alterations in mitochondrial function play a key part in the regulation of apoptosis. Moreover, the proteasome system has been shown to be implicated as a negative or positive mediator of apoptosis. The proteasome pathway is mostly known to work upstream of mitochondrial alterations and caspase activation.

Osteosarcoma is one of the most common primary malignant tumors of bone. Treatment of this tumor with systemic chemotherapy dramatically improves the prognosis. Numerous studies depicted that the therapeutic effect of a variety of chemotherapeutic agents on osteosarcoma depended on the induction of apoptosis. To date, there is no report about the synergistic apoptotic effects of co-treatment with VPA and HS-1200 on human osteosarcoma cells. Therefore, this study was undertaken to investigate the synergistic apoptotic effect of co-treatment with VPA, and a representative of CDCA derivative, HS-1200, on human osteosarcoma (HOS) cells.

II. MATERIALS AND METHODS

1. Reagents

The synthetic bile acid derivative, HS-1200 was kindly provided by Professor Young-Hyun Yoo (Department of Anatomy, College of Medicine, Dong-A University, Busan, Korea). The structure and methods of the synthesis of the synthetic bile acid derivatives were described (Im EO et al., 2001). HS-1200 is a conjugate form of CDCA with β-alanine benzyl ester (N-[3a, 5β, 7a]-3,7-dihydroxy-24-oxocholan -yl] β-alanine benzyl ester). The structures of CDCA and its conjugate form (HS-1200) are shown in Fig. 1.

The following reagents were obtained commercially: 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazol carbocyanine iodide (JC-1) was from Molecular Probes (Eugene, USA). Suc−LLVY−AMC was from Calbiochem (EMD Biosciences, Germany). Dulbecco’s modified Eagle’s
1. Chemical structures of CDCA and its derivative, HS-1200

medium (DMEM) and FBS were from Gibco (Gaithersburg, MD, USA). Dimethyl sulfoxide (DMSO), Hoechst 33342, RNase A, aprotinin, leupeptin, PMSF, thiazolyl blue tetrazolium bromide and propidium iodide (PI) were from Sigma (St. Louis, MO, USA); SuperSignal West Pico enhanced chemiluminescence Western blotting detection reagent was from Pierce (Rockford, IL, USA).

2. Antibodies

Mouse monoclonal anti-human caspase-3, caspase-7, poly(ADP-ribose) polymerase (PARP), cytochrome c, apoptosis-inducing factor (AIF) antibodies, and FITC-conjugated goat anti-mouse and anti-rabbit IgGs were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); HRP-conjugated sheep anti-mouse and anti-rabbit IgGs were from Amersham GE Healthcare (Little Chalfont, UK).

3. Cell culture

The HOS human osteosarcoma cell line was purchased from ATCC (Rockville, USA). Cells were maintained at 37°C with 5% CO₂ in air atmosphere in Dulbecco's modified Eagle's medium (DMEM) with 4 mM L-glutamine, 1.5 g/L sodium bicarbonate, 45 g/L glucose and 1.0 mM sodium pyruvate supplemented with 10% FBS.

4. Assessment of co-treatment of Valproic acid (VPA) and HS-1200

The stock solutions of VPA (2 M) made by dissolving the drug in PBS and HS-1200 (100 mM) made by dissolving the drug in ethanol were kept frozen at -20°C until use. Twenty four hours after HOS cells were subcultured, the original medium was removed. The cells were washed with phosphate-buffered saline (PBS) and then incubated in the same fresh medium. Since 1 mM VPA or 25 μM HS-1200 is approximately the highest concentration not to induce HOS cell death, we determined to utilize this single concentration of each chemical for the combination treatment study. HOS cells were co-treated with 1 mM VPA and 25 μM HS-1200 for 48 h. Cells were harvested, stained with trypan blue and then counted using a hemocytometer.

5. Hoechst staining

Cells were harvested and cell suspension was centrifuged onto a clean, fat-free glass slide with a cytocentrifuge. The samples were stained in 4 μg/mL Hoechst 33342 for 30 min at 37°C and fixed for 10 min in 4% paraformaldehyde.

6. Quantification of DNA hypoploidy by flow cytometry

After treatment for 48 h, cells were harvested by trypsinization and ice cold 95% ethanol with 0.5% Tween 20 was added to the cell suspensions to a final concentration of 70% ethanol. Fixed cells were pelleted, and washed in 1% BSA-PBS solution. Cells were resuspended in 1 mL PBS containing 20 μg/mL RNase A, incubated at 4°C for 30 min, washed once with BSA-PBS, and resuspended in PI solution (10 μg/mL). After cells were incubated at 4°C for 5 min in the dark, DNA content were measured on a CYTOMICS FC500 flow cytometry.
system (Beckman Coulter, FL, CA, USA) and data was analyzed using the Multicycle software which allowed a simultaneous estimation of apoptosis.

7. Assay of mitochondrial membrane potential (MMP)

JC-1 was added directly to the cell culture medium (1 μM final concentration) and incubated for 15 min. The medium was then replaced with PBS. Flow cytometry to measure MMP was performed on a CYTOMICS FC500 flow cytometer (Beckman Coulter, FL, CA, USA). Data were acquired and analyzed using CXP software version 2.2.

8. Immunofluorescent staining

Cells were cytocentrifuged and fixed for 10 min in 4% paraformaldehyde, incubated with each primary antibody for 1 h, washed 3 each for 5 min, and then incubated with FITC-conjugated secondary antibody for 1 h at room temperature. Cells were mounted with PBS. Fluorescent images were observed and analyzed under Zeiss LSM 510 laser-scanning confocal microscope (Goettingen, Germany).

9. Western blot analysis

Cells (2 x 10⁶) treated with VPA and/or HS-1200 were washed twice with ice-cold PBS, resuspended in 200 μL ice-cold solubilizing buffer [300 mM NaCl, 50 mM Tris–Cl (pH 7.6), 0.5% Triton X-100, 2 mM PMSF, 2 μL/mL aprotinin and 2 μL/mL leupeptin] and incubated at 4°C for 30 min. The lysates were centrifuged at 14,000 revolutions per min for 15 min at 4°C. Protein concentrations of cell lysates were determined with Bradford protein assay (Bio-Rad, USA) and 50 μg of proteins were loaded onto 7.5-15% SDS/PAGE. The gels were transferred to Nitrocellulose membrane (Amerham Pharmacia Biotech, UK) and reacted with each antibody. Immunostaining with antibodies was performed using SuperSignal West Pico enhanced chemiluminescence substrate and detected with Alpha Imager HP (Alpha Innotech, USA).

III. RESULTS

1. Co-treatment of VPA and HS-1200 augmented the reduction in viability of HOS cells.

Single treatment of VPA at 1 mM or HS-1200 at 25 μM for 48 h reduced viability of HOS cells, slightly (VPA, 89.00%; HS-1200, 83.84%). Co-treatment of VPA and HS-1200 significantly reduced cell viability compared to the effect of each single treatment (co-treatment, 35.92%) (Fig. 2).

2. Co-treatment of VPA and HS-1200 augmented the nuclear condensation and fragmentation in HOS cells.

To explore whether nuclear condensation and fragmentation were induced, Hoechst staining which is a hallmark of apoptosis, was conducted.

![Fig. 2. Co-treatment of VPA and HS-1200 significantly reduced cell viability in HOS cells. Cell viability was determined by hemocytometer. Three independent assays were performed. Values are means ± SD of triplicates of each experiment. V, cells treated with 1 mM VPA for 48 h; H, cells treated with 25 μM HS-1200 for 48 h; V+H, cells treated with 1 mM VPA plus 25 μM HS-1200 for 48 h.](image-url)
Apoptotic Effect of Co-Treatment with Valproic Acid and HS-1200 on Human Osteosarcoma Cells

Fig. 3. Immunofluorescent micrographs showing nuclear morphology after Hoechst staining. Co-treatment of VPA and HS-1200 showed numerous condensed and fragmented nuclei in HOS cells compared to the single treatment (V, cells treated with 1 mM VPA for 48 h; H, cells treated with 25 \( \mu \)M HS-1200 for 48 h; V+H, cells treated with 1 mM VPA plus 25 \( \mu \)M HS-1200 for 48 h).

The co-treatment of VPA and HS-1200 showed a variety of condensed and fragmented nuclei compared to the single treatment (Fig. 3).

3. Augmentation of apoptosis by co-treatment of VPA and HS-1200 was demonstrated by the decrease of DNA content in HOS cells.

The flow cytometry showed that co-treatment of VPA and HS-1200 remarkably increased apoptotic cells with DNA hypoploidy compared to the single treatment (Fig. 4).

Fig. 4. The kinetic analysis of the effect of co-treatment on HOS cell cycle progression and induction of apoptosis by flow cytometry. Co-treatment remarkably showed the increase of apoptotic cells with DNA hypoploidy compared to the single treatment (V, cells treated with 1 mM VPA for 48 h; H, cells treated with 25 \( \mu \)M HS-1200 for 48 h; V+H, cells treated with 1 mM VPA plus 25 \( \mu \)M HS-1200 for 48 h).

4. Augmentation of apoptosis by co-treatment of VPA and HS-1200 was demonstrated by reduction of mitochondrial membrane potential (MMP) in HOS cells.

The single treatment of VPA and HS-1200 did not show the loss of MMP compared to control group. But the co-treatment of VPA and HS-1200 remarkably reduced MMP compared to the single treatment (Fig. 5).

5. Efficient apoptotic effect of co-treatment of VPA and HS-1200 was demonstrated by Western blot assay.

The co-treatment of VPA and HS-1200 induced the degradation of caspase-3, caspase-7 and PARP whereas the single treatment did not (Fig. 6).
Fig. 5. Co-treatment of VPA and HS-1200 remarkably showed the loss of MMP ($\Delta \varphi_m$) compared to the single treatment. MMP was measured by JC-1 with flow cytometry (V, cells treated with 1 mM VPA for 48 h; H, cells treated with 25 $\mu$M HS-1200 for 48 h; V+H, cells treated with 1 mM VPA plus 25 $\mu$M HS-1200 for 48 h).

6. Co-treatment of VPA and HS-1200 showed to lead to the translocation of AIF from mitochondria onto the nuclei.

The confocal microscopy showed that AIF was located at mitochondria in the single treatment of VPA or HS-1200 whereas AIF was evidently translocated onto nuclei in the co-treatment (Fig. 7).

7. Co-treatment of VPA and HS-1200 showed to lead to the release of cytochrome c from mitochondria into the cytosol.

The confocal microscopy showed that cytochrome c was located at mitochondria in the single treatment of VPA or HS-1200 whereas cytochrome c was evidently released into the cytosol in the co-treatment (Fig. 8).
IV. DISCUSSION

VPA was employed as monotherapy or combination therapy for various types of malignancy. These studies indicated that VPA as monotherapy or combination therapy showed antiproliferative activity on cancer cells. It is noticeable that VPA, at concentrations of clinical interest, significantly enhanced the antiproliferative activity. This range of concentrations of VPA can be achieved in an patient’s serum when receiving a daily dose of 20–30 mg/kg for epilepsy. Thus, VPA is being considered as a promising potential therapeutic agent for cancers. Combination anticancer therapies using VPA and other drugs, especially non-toxic drugs, may offer a substantial advantage over VPA monotherapy in a clinical setting. VPA combined with all-trans retinoic acid or interferon alpha (IFN-α) has been demonstrated to enhance the efficacy of each antitumor agent. We, in the present study, designed three VPA-based combination anticancer therapies using HS-1200 for HOS.

It has been reported the antiproliferative efficacy of synthetic CDCA derivatives in various cancer cells by inducing apoptosis. Those studies demonstrated the decrease of proteasome activity, mitochondrial events, and nuclear condensation in synthetic CDCA derivatives-induced apoptosis. In addition, it has been demonstrated that a synthetic CDCA derivative, HS-1200 shows the strongest apoptosis-inducing effect among the synthetic CDCA derivatives.

Mitochondria plays an important role in apoptosis, induction of the mitochondrial permeability transition play a key part in the regulation of apoptosis. Outer mitochondrial membrane becomes permeable to intermembrane space proteins such as cytochrome c and AIF (apoptosis inducing factor) during apoptosis. Cytochrome c release and disruption of mitochondrial membrane potential (MMP) are in fact known features in apoptosis triggered by proteasome inhibition. On induction of apoptosis, AIF translocates to the nucleus, resulting in chromatin condensation and large-scale DNA fragmentation. This study evidently showed that co-treatment with CGM and HS-1200 in HOS cells results in significant decrease of MMP, the release of cytochrome c into cytosol and the translocation of AIF onto nuclei whereas the single treatment does not.

A common final event of apoptosis is nuclear condensation, which is controlled by caspases, DFF, and PARP. Caspases, the cysteinyl aspartate-specific intracellular protease, play an essential role during apoptotic death. Once activated, the effector caspases (caspase-3, caspase-6 or caspase-7) are responsible for the proteolytic cleavage of a broad spectrum of cellular targets, leading ultimately to cell death. This study demonstrated that co-treatment with CGM and HS-1200 in HOS cells results in the degradation of caspase-3, caspase-7 and PARP whereas the single treatment does not.

In the study, HOS cells co-treated with VPA and HS-1200 showed several lines of apoptotic manifestation such as nuclear condensations, the
decrease of MMP; the decrease of DNA content, the release of cytochrome c into cytosol, the translocation of AIF, and degradation of caspase-7, caspase-3 and PARP whereas each single treated HOS cells did not. In conclusion, combination therapy of VPA and HS-1200 could be considered, in the future, as an alternative therapeutic strategy for human osteosarcoma. Its clinical application awaits further extensive studies.

V. CONCLUSION

Valproic acid (VPA) is a well-known anticonvulsive agent and has been used in the treatment of epilepsy for almost 30 years. VPA emerged in 1997 as an antineoplastic agent as well, when findings indicated the substance inhibited proliferation and induced differentiation of primitive neuroectodermal tumor cells in vivo (Cinatl et al., 1997). Antitumor activity of VPA is associated with its targeting histone deacetylases. Bile acids and their synthetic derivatives induced apoptosis in various kinds of cancer cells and anticancer effects. It has been reported that the synthetic chenodeoxycholic acid (CDCA) derivatives showed apoptosis–inducing activity on various cancer cells in vitro. This study was undertaken to investigate the synergistic apoptotic effect of co-treatment with the histone deacetylases inhibitor, VPA and a CDCA derivative, HS-1200 on human osteosarcoma (HOS) cells.

Cell viability was evaluated by trypan-blue exclusion. Induction and augmentation of apoptosis were confirmed by Hoechst staining, flow cytometry (DNA hypoploidy and MMP change), Western blot analysis and immunofluorescent staining.

In this study, HOS cells co-treated with VPA and HS-1200 showed several lines of apoptotic manifestation such as nuclear condensations, the reduction of MMP, the decrease of DNA content, the release of cytochrome c into cytosol, the translocation of AIF onto nuclei, and activation of caspase-7, caspase-3 and PARP whereas each single treated HOS cells did not. Although the single treatment of 1 mM VPA or 25 μM HS-1200 for 48 h did not induce apoptosis, the co-treatment of them induced prominently apoptosis. Therefore our data provide the possibility that combination therapy of VPA and HS-1200 could be considered as a novel therapeutic strategy for human osteosarcoma.

REFERENCES

30. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Gsp1, CDK4, and CMYC. Mol Cancer Ther


국문초록

Valproic acid와 HS-1200의 병용처리가 사람골육종세포에 미치는 세포자멸사 효과에 대한 연구

1부산대학교 치의학전문대학원 구강해부학교실, 2부산대학교 치의학전문대학원 구강내과학교실

김덕한1 ⋅ 이기현1 ⋅ 곽현호1 ⋅ 박봉수1 ⋅ 정성희2 ⋅ 고명연2 ⋅ 안용우2

Valproic acid(VPA)는 아주 잘 알려진 항경련제로서, 30년 동안 간질치료제로서 사용되어 왔다. VPA는 1997년에 최초로 원시 신경외배엽성 임세포의 증식 억제와 분화를 유도하는 항암제의 효능이 밝혀졌다. 그리고 VPA의 항암효과는 히스톤아세틸화효소억제제의 기전에 기인한다고 규정되었다. 담즙산과 합성담즙산유도체가 여러 종류의 임세포에 세포자멸사(apoptosis)를 유도하며, 항암효과가 있다고 알려져 있다. 또한 질환 chenodeoxycholic acid(CDCA) 유도체가 여러 가지 임세포에 유도한 세포자멸사 연구들이 보고되어 왔다. 본 연구는 히스톤아세틸화효소억제제인 VPA와 합성 CDCA 유도체인 HS-1200의 병용처리가 사람골육종세포에 효과적인 상승 세포자멸사 효과가 있는지를 알아보기 위해 수행되었다.

VPA와 HS-1200의 병용처리가 단독처리에 비해서 효과적인 세포생존율 감소가 있는지 확인하기 위해서 trypan blue법을 시행하였고, 세포자멸사의 유도를 확인하기 위해서 Hoechst 염색법, flow cytometry(DNA hypoploidy와 MMP 측정), Western blot 분석법 그리고 면역형광염색법을 수행하였다.

병용처리 된 사람골육종세포는 단독처리 된 사람골육종세포에서 거의 관찰할 수 없었던 많은 핵 응축, DNA 조각남, 사람 세포의 전위와 DNA 양의 감소, cytochrome c의 세포질로의 유출, AIF의 핵으로의 이송, caspase-7, caspase-3 그리고 PARP의 파괴와 같은 세포자멸사 증상을 보였다. 48시간 동안 1 mM의 VPA와 25 μM HS-1200을 각기 단독처리 한 결과에서는 세포자멸사를 유도 못했으나, 병용처리한 결과에는 아주 탁월한 세포자멸사의 유도를 보였다. 이러한 병용처리 결과는 사람골육종의 새로운 치료적 전략으로 활용될 수 있다고 생각한다.

Key words : 세포자멸사, valproic acid, HS-1200, 사람골육종